<DOC>
	<DOCNO>NCT02013336</DOCNO>
	<brief_summary>This Phase 1 study combination two drug : MM-398 Cyclophosphamide . The goal find high dose MM-398 give safely use together chemotherapy drug Cyclophosphamide .</brief_summary>
	<brief_title>Phase 1 Study MM-398 Plus Cyclophosphamide Pediatric Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically cytologicallyconfirmed Ewing sarcoma , rhabdomyosarcoma , neuroblastoma , osteosarcoma Disease progression prior therapy locally advanced metastatic set Measurable evaluable disease base Response Evaluation Criteria Solid Tumors ( RECIST v1.1 ) criterion Age 12 month &lt; 21 year Adequate bone marrow reserve , hepatic function , renal function Recovered effect prior surgery cancer therapy Patients 18 year old provide write consent . A parent legal guardian patient &lt; 18 year age provide inform consent patient 11 18 year age provide write assent per participate institutional policy . Clinically significant gastrointestinal disorder NYHA Class III IV congestive heart failure , ventricular arrhythmia uncontrolled blood pressure Active infection unexplained fever Known hypersensitivity component MM398 liposomal product Recent Investigational therapy Pregnant breast feeding ; female childbearing potential must test negative pregnancy time enrollment</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>pediatric</keyword>
	<keyword>MM-398</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>irinotecan</keyword>
</DOC>